Scholarlink

<p>We report a 71-year-old man with confirmed giant cell arteritis (GCA) who underwent temporal artery biopsy. Following 2.5 years of combination therapy with tocilizumab (TCZ) (162&#xa0;mg/w) and glucocorticoids (tapered over 2.5 years to prednisolone 1&#xa0;mg/day), erythematous facial papules and red eye developed. Skin biopsy revealed multiple non-caseating epithelioid granulomas containing multinucleated giant cells, without evidence of infection. Serum angiotensin-converting enzyme levels and soluble interleukin-2 receptor levels were within normal limits, and imaging showed no systemic sarcoidosis involvement. TCZ-induced sarcoidosis-like reaction was suspected. TCZ was discontinued 3 months after the onset of the lesions. Considering the risk of GCA recurrence, PSL was increased to 2&#xa0;mg/day. The erythematous facial papules and red eye showed improvement 5 months after the onset of the lesions. There was no GCA recurrence. Biologic agents including TCZ are cornerstones in autoimmune disease management but may paradoxically induce immune-mediated reactions, including sarcoidosis-like reactions due to immune dysregulation. A literature search identified 6 previously published cases of TCZ-associated sarcoidosis-like reactions. Among these, ocular involvement in the form of scleritis was observed only in the present case. We should remain vigilant for sarcoidosis-like reaction during TCZ therapy and consider individualized monitoring and treatment adjustment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sarcoidosis-like reaction associated with tocilizumab in a patient with giant cell arteritis: a case based review

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Misako Higashida-Konishi,
  • Shiori Kusano,
  • Hiroki Tabata,
  • Satoshi Hama,
  • Tatsuhiro Oshige,
  • Yuriko Yukino,
  • Keisuke Izumi,
  • Arafumi Maeshima,
  • Yutaka Okano,
  • Hisaji Oshima,
  • Katsuya Suzuki

摘要

We report a 71-year-old man with confirmed giant cell arteritis (GCA) who underwent temporal artery biopsy. Following 2.5 years of combination therapy with tocilizumab (TCZ) (162 mg/w) and glucocorticoids (tapered over 2.5 years to prednisolone 1 mg/day), erythematous facial papules and red eye developed. Skin biopsy revealed multiple non-caseating epithelioid granulomas containing multinucleated giant cells, without evidence of infection. Serum angiotensin-converting enzyme levels and soluble interleukin-2 receptor levels were within normal limits, and imaging showed no systemic sarcoidosis involvement. TCZ-induced sarcoidosis-like reaction was suspected. TCZ was discontinued 3 months after the onset of the lesions. Considering the risk of GCA recurrence, PSL was increased to 2 mg/day. The erythematous facial papules and red eye showed improvement 5 months after the onset of the lesions. There was no GCA recurrence. Biologic agents including TCZ are cornerstones in autoimmune disease management but may paradoxically induce immune-mediated reactions, including sarcoidosis-like reactions due to immune dysregulation. A literature search identified 6 previously published cases of TCZ-associated sarcoidosis-like reactions. Among these, ocular involvement in the form of scleritis was observed only in the present case. We should remain vigilant for sarcoidosis-like reaction during TCZ therapy and consider individualized monitoring and treatment adjustment.